<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01871415</url>
  </required_header>
  <id_info>
    <org_study_id>YC28036</org_study_id>
    <nct_id>NCT01871415</nct_id>
  </id_info>
  <brief_title>A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy</brief_title>
  <official_title>A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ALEGLITAZAR PLUS METFORMIN COMBINATION THERAPY COMPARED WITH PLACEBO PLUS METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED WITH METFORMIN MONOTHERAPY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multicenter, randomized, double-blind, placebo-controlled study will evaluate the
      efficacy, safety and tolerability of aleglitazar in combination with metformin in patients
      with Type 2 diabetes mellitus who are inadequately controlled with metformin monotherapy.
      Patients will be randomized to receive either aleglitazar 150 mcg orally daily or placebo for
      26 weeks in combination with their pre-existing metformin regimen and dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>from baseline to Week 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lipids</measure>
    <time_frame>from baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG)</measure>
    <time_frame>from baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rates, defined as target HbA1c: &lt; 7.0%, &lt; 6.5% at Week 26</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in homeostatic index of insulin sensitivity (by HOMA-IS)</measure>
    <time_frame>from baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in homeostatic index of beta cell function (by HOMA-BFC)</measure>
    <time_frame>from baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markers of insulin sensitivity/cardiovascular risk</measure>
    <time_frame>from baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 30 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Aleglitazar + metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aleglitazar</intervention_name>
    <description>150 mcg orally daily</description>
    <arm_group_label>Aleglitazar + metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>pre-existing background regimen and dose</description>
    <arm_group_label>Aleglitazar + metformin</arm_group_label>
    <arm_group_label>Placebo + metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching aleglitazar placebo orally daily</description>
    <arm_group_label>Placebo + metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient, &gt;/= 18 years of age

          -  Type 2 diabetes mellitus treated with stable metformin monotherapy for at least 12
             weeks prior to screening; metformin dose should be &gt;/= 1500 mg/day (or individual
             maximum tolerated dose), but no more than the maximum dose specified in the label

          -  HbA1c &gt;/= 7% and &lt;/= 9.5% at screening or within 4 weeks prior to screening and at
             pre-randomization visit

          -  Fasting plasma glucose &lt;/= 13.3 mmol/L (&lt;/= 240 mg/dL) at pre-randomization visit

          -  Agreement to maintain diet and exercise habits implemented during the run-in phase
             during the full course of the study

        Exclusion Criteria:

          -  Pregnant women, women intending to become pregnant during the study period, currently
             lactating women, or women of child-bearing potential not using highly effective,
             medically approved birth control methods

          -  Diagnosis or history of:

               1. Type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or secondary
                  forms of diabetes

               2. Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma
                  within the past 6 months

          -  Any previous treatment with thiazolidinedione or with a dual PPAR agonist

          -  Any body weight lowering or lipoprotein-modifying therapy (e.g. fibrates) within 12
             weeks prior to screening with the exception of stable (&gt;= 1 month) statin therapy

          -  Prior intolerance to fibrate

          -  Treatment with anti-diabetic medication other than metformin in the last 12 weeks
             prior to screening

          -  Triglycerides (fasting) &gt; 4.5 mmol/L (&gt; 400 mg/dL) at screening or within 4 weeks
             prior to screening

          -  Clinically apparent liver disease

          -  Anemia at or within 4 weeks prior to screening

          -  Inadequate renal function

          -  Symptomatic congestive heart failure NYHA Class II-IV at screening

          -  Myocardial infarction, acute coronary syndrome or transient ischemic attack/stroke
             within 6 months prior to screening visit

          -  Known macular edema at screening or prior to screening visit

          -  Diagnosed and/or treated malignancy (except for basal cell skin cancer, in situ
             carcinoma of the cervix, or in situ prostate cancer) within the past 5 years

          -  Uncontrolled hypertension

          -  History of active substance abuse (including alcohol) within the past 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>ShenYang</city>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shiyan</city>
        <zip>442000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suzhou</city>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyeonggi-do</city>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>150-950</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2013</study_first_submitted>
  <study_first_submitted_qc>June 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2013</study_first_posted>
  <disposition_first_submitted>August 9, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>August 9, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 11, 2016</disposition_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

